SCHEMBL23922794

SCHEMBL23922794

COC(=O)Cn1c(/C=C/C(=O)O)cccc1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
ALDH1A1 P00352 4/20 0.42
HSD17B10 Q99714 3/20 0.42
CDK4 P11802 1/20 0.40
CCND1 P24385 1/20 0.40
CCND2 P30279 1/20 0.40
CCND3 P30281 1/20 0.40
TSHR P16473 2/20 0.38
MEN1 O00255 1/20 0.38
GLA P06280 1/20 0.38
GAA P10253 1/20 0.38
KMT2A Q03164 1/20 0.38
RCE1 Q9Y256 1/20 0.38
TBXAS1 P24557 1/20 0.36
POLB P06746 1/20 0.36
ALOX15 P16050 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
THRB P10828 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28833433 0.84 KDM4E (0.43) KDM4ESMN1; SMN2ALDH1A1HSD17B10TSHR
SCHEMBL9207480 0.74 KDM4E (0.56) KDM4ESMN1; SMN2ALDH1A1HSD17B10CDK4
SCHEMBL22114352 0.73 KDM4E (0.54) KDM4ESMN1; SMN2ALDH1A1HSD17B10CDK4
SCHEMBL29959857 0.73 KDM4E (0.54) KDM4ESMN1; SMN2ALDH1A1HSD17B10CDK4
SCHEMBL16831833 0.72 TBXAS1 (0.43) KDM4ESMN1; SMN2ALDH1A1KMT2ATBXAS1
SCHEMBL16831832 0.72 TBXAS1 (0.43) KDM4ESMN1; SMN2ALDH1A1KMT2ATBXAS1
SCHEMBL9205380 0.71 KDM4E (0.51) KDM4ESMN1; SMN2ALDH1A1HSD17B10CDK4
SCHEMBL28833166 0.67 KDM4E (0.43) KDM4ESMN1; SMN2ALDH1A1TSHRMEN1
SCHEMBL27473454 0.67 KDM4E (0.50) KDM4ESMN1; SMN2ALDH1A1HSD17B10TSHR
SCHEMBL28833157 0.65 KDM4E (0.42) KDM4ESMN1; SMN2ALDH1A1TSHRGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3895707-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2023-10-04 EP disclosed
US-20230042358-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-02-09 US disclosed
EP-3895707-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2021-10-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230042358-A1 HETEROCYCLIC COMPOUND HCRTR2, HCRTR1, NTSR2 KDM4E 1355/4885SMN1; SMN2 1031/4885ALDH1A1 1746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.